AstraZeneca's diabetes drug Xigduo approved in Europe

LONDON Wed Jan 22, 2014 2:28am EST

LONDON Jan 22 (Reuters) - AstraZeneca said European regulators had approved Xigduo for type 2 diabetes, in what was the first green light for a fixed dose combination of a SGLT2 inhibitor and metformin.

The drug combines in a twice daily tablet Forxiga, a SGLT2 inhibitor that reduces the reabsorption of excess glucose, and metformin, a standard in treating the condition.

Xigduo was developed by the alliance in diabetes therapy between the British company and Bristol-Myers Squibb, the companies said on Wednesday. AstraZeneca will take full control of the unit later this quarter.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.